Northern Trust Corp Buys 50,992 Shares of Seer, Inc. (NASDAQ:SEER)

Northern Trust Corp grew its stake in Seer, Inc. (NASDAQ:SEER) by 48.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 155,617 shares of the company’s stock after purchasing an additional 50,992 shares during the period. Northern Trust Corp owned approximately 0.26% of Seer worth $359,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of SEER. Peapod Lane Capital LLC bought a new stake in shares of Seer in the 4th quarter valued at approximately $991,000. Renaissance Technologies LLC lifted its stake in shares of Seer by 27.0% in the 4th quarter. Renaissance Technologies LLC now owns 843,700 shares of the company’s stock valued at $1,949,000 after purchasing an additional 179,568 shares during the last quarter. Fuller & Thaler Asset Management Inc. bought a new stake in shares of Seer in the 4th quarter valued at approximately $179,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Seer in the 4th quarter valued at approximately $36,000. Finally, Corient Private Wealth LLC lifted its stake in shares of Seer by 66.0% in the 4th quarter. Corient Private Wealth LLC now owns 33,200 shares of the company’s stock valued at $77,000 after purchasing an additional 13,200 shares during the last quarter. 75.20% of the stock is owned by institutional investors.

Seer Price Performance

NASDAQ:SEER opened at $1.98 on Monday. The firm has a market capitalization of $116.27 million, a price-to-earnings ratio of -1.52 and a beta of 1.58. Seer, Inc. has a 1 year low of $1.56 and a 1 year high of $2.63. The business has a 50 day simple moving average of $1.94 and a 200-day simple moving average of $2.16.

Seer (NASDAQ:SEER) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.03. The business had revenue of $4.21 million during the quarter, compared to analyst estimates of $3.25 million. Seer had a negative return on equity of 21.96% and a negative net margin of 565.83%. As a group, analysts expect that Seer, Inc. will post -1.42 earnings per share for the current fiscal year.

Seer Company Profile

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.